Fast responding to Scott Gottlieb, FDA Commissioner’s statement on 7th March that the naming guide that requires a four letter suffix attached to the nonproprietary name of biological drugs will now only apply to biosimilars, Prof. Niazi, filed a citizen petition demanding the FDA to withdraw the guidance to prevent vested interests from misguiding prescribers and patients that biosimilars have different safety and efficacy.
March 19, 2019
· 2 min read